Infections in cirrhotic patients
Ahmed El Shabrawi, Mohammed Abdelaziz, Nasser Mousa

Summary
Cirrhosis is considered to be the final stage of various liver injuries. Cirrhotic patients are more vulnerable to an increased incidence of infections than normal population. Various theories had been postulated to explain the higher frequency of infections among cirrhotic patients including alterations in the enteric flora, dysfunction of the intestinal barrier and impairment of the host defense mechanisms. In particular, bacterial infections could be a precipitating factor for deterioration of the liver condition and occurrence of number of life threatening complications such as acute on top of chronic liver failure (ACLF), acute kidney injury, hepatic encephalopathy, coagulation defect and variceal bleeding. Among the infections described in cirrhotic patients, spontaneous bacterial peritonitis, pneumonia, urinary tract infection, soft tissue infection, and bacteremia were found to be the most repeatedly encountered. Assuming that, infections in cirrhotic patients are considered as alarming signs, prompt and definitive management strategies should be undertaken. This manuscript focuses on bacterial infections in cirrhotic patients as regard pathophysiology, types, consequences and management.

Keywords: Cirrhosis, Infection, Spontaneous bacterial peritonitis and acute on top of chronic liver failure

Introduction
Cirrhosis is the end stage of a chronic liver disease lead to a syndrome called cirrhosis-associated immune dysfunction syndrome (CAIDS). The resultant development of CAIDS disables the habitual efficient protection against different infections. Cirrhotic patients have an increased incidence of infections that are a chief cause of morbidity and mortality. In addition to alterations in the enteric flora and the intestinal barrier due to portal hypertension, susceptibility to infection can be documented to an impairment of the defense mechanisms against infections. A number of dysfunctions of the reticuloendothelial system, neutrophil granulocyte functions, humoral and cell-mediated immunity have been described in patients with cirrhosis. Furthermore, those living with cirrhosis can report a high predisposition to sepsis and septic shock, due to the excessive response of pro-inflammatory cytokines and hemodynamic derangement. Spontaneous bacterial peritonitis, pneumonia, urinary tract infection, soft tissue infection, and bacteremia are the most common infection described in cirrhotic.

Cirrhosis and Immunity
The physiological abilities to know antigens and activation of the immune response are mutually linked and coordinated so that the immune response to the pathogen can be as efficient and quick as possible. In the case of cirrhosis, there are some irregularities of the immunological response. They can change dynamically at different stages of the illness (balanced cirrhosis, decompensated cirrhosis, and acute cirrhosis) and they are also dependent on the organ damage and stimulating factors, e.g. bacterial translocation. In the development of CAIDS, the tolerance of monocytes towards
endotoxins and bacterial antigens plays a significant role. The tolerance develops as a result of the low density of the above-mentioned factors as well as their penetration through the damaged intestinal barrier\(^\text{12}\). The liver acts as a bacterial filter. Its phagocytic system reticulo-endothelial system (RES) plays an important role in the elimination of intestinal bacteria and endotoxins\(^\text{13}\). In cirrhotic patients, the essential functions of RES are weakened and the number and the efficiency of stellar cells (Kupffer cells, hepatic macrophages) are decreasing\(^\text{14,15}\). Moreover, in cirrhosis there is disturbed synthesis of proteins responsible for the innate immune resistance and reduction of the secretion of receptors responsible for antigen recognition, all of which decreases the antibacterial action of cytophages. These conditions are mostly visible in the case of advanced cirrhosis and ascites (characterized by small levels of complements C3, C4, C50 in the serum and effusion fluid) and they tend to result in increased susceptibility to various bacterial infections\(^\text{16,17}\). The crucial role of these irregularities is played by genetic polymorphisms of receptors responsible for the pattern recognitions of toll like receptors (TLR) and nucleotide-binding oligomerization domain 2 (NOD2). As a result, these receptors are less professional in binding polysaccharides and/or bacterial endotoxins, which expose the affected patients to coinciding and/or ensuing infections\(^\text{18}\).

**Pathogenesis of Bacterial Infections**

Many factors interacting in producing bacterial infections in cirrhosis including, gut microbiota, intestinal permeability, bacterial translocation (BT) and immune deficiency which may be acquired or conferred by genetic susceptibility\(^\text{19}\).

**Gut microbiota**

An essential tip to prevent pathological BT is to maintain gut bacteria under very tight control. On the other hand, intestinal bacteria contribute to symbiosis by educating and maintaining the host immune system. Disproportion of this fine homeostasis between host and microbiome can direct to disease\(^\text{20-22}\). Alteration in the microbiome occurs as quantitative intestinal bacterial overgrowth (IBO) or qualitative (dysbiosis) changes. IBO is a common feature in cirrhotic patients and occurs mostly in the small intestine\(^\text{23-25}\). IBO is multifactorial, and causative factors include modulation of gastric acid secretion, decline in intestinal motility, lack of bile constituents and antimicrobial peptides in addition to portal hypertension\(^\text{26-31}\). Patients with cirrhosis and IBO more frequently have SBP compared to patients without bacterial overgrowth\(^\text{31}\). Experimental IBO itself can result in microbial translocation and liver inflammation\(^\text{32}\), documenting the importance of quantitative microbiome changes. Moreover, deceasing the intestinal bacterial burden with antibiotics ameliorates experimental liver disease\(^\text{33,34}\) and, decreases the liver disease severity\(^\text{35,36}\) and infectious complications in patients with advanced cirrhosis.

**Intestinal barrier dysfunction**

Increased intestinal permeability has been established by different methods and shown to be mostly found in advanced stages of disease and septic complications. Tight junctions (TJ) between epithelial cells limit paracellular permeation and thus translocation of bacterial products. Changes in TJ proteins are present in cirrhosis and most possible loosen TJ-function\(^\text{37,38}\). Transcytosis appears to represent the major route but is poorly defined in cirrhosis. One of the key regulators modulating TJ and transcytosis is tumor necrosis factor-\(\alpha\), which is increased in the gut-associated lymphatic tissue in advanced cirrhosis\(^\text{39,40}\). Many mediators that can limit the direct contact of intestinal bacteria to the epithelial surface such as IgA\(^\text{41}\), biliary lipids\(^\text{42}\), and antimicrobial peptides are deficient in cirrhotic patients\(^\text{30}\). Also, in cirrhotic patients there is deficiency in expression of the antimicrobial protein Reg3\(\gamma\), which maintains a physical barrier between the epithelial cell surface and intestinal microbes\(^\text{43}\).

**Consequences of Bacterial Infections**

Bacterial infection is a most important cause of acute decompensation of cirrhosis even associated with failure in other organs and high risk of short-term death\(^\text{44-47}\). These patients are considered to have acute-on-chronic liver failure\(^\text{46}\). A large prospective
observational study (CANONIC study) used the CLIF-Sequential Organ Failure Assessment (SOFA) score to recognize organ failures classified ACLF into three ACLF grades, with increasing risk of short-term death from grade 1 (22%) to grade 3 (77%)\(^4\). Bacterial infection was the most common precipitating event of ACLF (33%)\(^4\) and ACLF was more recurrent in patients with SBP or pneumonia than in those with infections at other sites\(^4,49\).

**Infection and liver Damage**
The liver damage as a consequence of infection depends on both, the intensity of the inflammatory response and the intrinsic capacity of the liver to tolerate the effects of the inflammatory response. This tolerance depends on inducible mechanisms such as anti-apoptotic pathways\(^5\). In the situation of Gram-negative infections, normal liver is protected against LPS-induced, TNF-α-mediated apoptosis because of synchronized induction of nuclear factor-κB (NF-κB)-dependent anti-apoptotic molecules\(^5\). However, cirrhotic liver is abnormally susceptible to LPS-induced, TNF-α-mediated apoptosis since NF-κB-target anti-apoptotic molecules cannot be correctly induced\(^5\). Thus, in cirrhotic patient, infection-produced liver failure may be related to both, an extreme pro-inflammatory response and reduction in the hepatic capacity of tolerance.

**Kidney Failure**
Bacterial infections\(^5,53\) are well-established triggers of kidney failure in cirrhotic patient. Patients with SBP lacking shock who shows the highest pro-inflammatory response are those who are at risk of developing kidney failure\(^5\). Significantly, in these patients, kidney failure frequently develops while resolution of infection has been obtained by antibiotic therapy\(^5\) signifying that, organ failure does not result from intrinsic virulence (i.e., tissue damage directly caused by bacteria) but rather extrinsic virulence (i.e., produced by the excessive inflammatory response of the host) or sepsis-related alterations in hemodynamics\(^5\). A potential role for alterations of tolerance mechanisms in the development of kidney failure\(^54\) has not yet been investigated.

**Brain Failure**
Bacterial infections are recurrent precipitating factor of hepatic encephalopathy\(^55\). Data reveal that, infections may produce brain oedema in cirrhotic patient. It is currently uncertain whether this water accumulation is predominantly intracellular or extracellular. There is some evidence that both mechanisms combine to cause brain edema and hepatic encephalopathy (HE)\(^56\).

**Coagulation Failure**
Infection in cirrhotic patients specially if associated with ACLF is connected with disseminated intravascular coagulation (DIC), which can be activated by pro-inflammatory cytokines compared to patients free from ACLF\(^47\). Thrombi in the microvasculature of a vital organ may engage in tissue hypoxia\(^50\). Important, activation of coagulation may stimulate inflammation\(^50\).

**Variceal Bleeding**
Bleeding from esophageal varies is a well-documented risk factor for bacterial infection in patients with cirrhosis\(^57\). Furthermore, it has been proposed that conversely bacterial infection might increase the risk of variceal hemorrhage\(^58\).

**Adrenal Insufficiency**
Patients with cirrhosis and septic shock may have high incidence of relative adrenal insufficiency (RAI)\(^59\). This RAI seems to be linked with poor liver function, kidney failure, refractory shock and hospital mortality\(^60\). RAI could result in decreased corticosteroid-related anti-inflammatory mechanisms and as a result unrestricted infection creates pro-inflammatory molecules. In addition, under stress conditions, defective corticosteroid production could be associated with decreased capacity of tolerance of vital organs\(^50,61\). Serum total cortisol overestimates the prevalence of RAI in cirrhosis due to low transcortin and albumin concentrations so that, free cortisol levels have been optional method for the diagnosis of\(^62,63\). Also, the
value of delta total cortisol as a diagnostic marker of RAI not affected by changes in transcortin or albumin levels.

Spontaneous Bacterial Peritonitis

Spontaneous bacterial peritonitis (SBP) is a bacterial infection of previously sterile ascitic fluid in the absence of other intra-abdominal source of infection. The development of SBP may occur in patients with ascites regardless of its etiology. SBP present in 10-30% of hospitalized patients with cirrhosis and ascites. It is one of the major bacterial infections in this group of patients and is associated with severe prognosis. The 30-day mortality rate is estimated at 26-48.7%. SBP, accounting for 22.5% of infectious etiology of acute on chronic liver failure. After the SBP episode, the 1-year survival rate is estimated at 30% to 50% and 5-year survival at 15.2%. The hepatorenal syndrome occurs in 33% of patients with SBP and is the strongest predictor of in-hospital mortality in this patients. Infection may be manifested as the systemic inflammatory response syndrome (SIRS), sepsis, multiple organ failure, acute on chronic liver failure and death. Gram-positive bacteria were responsible for about 1/4 episodes of SBP. However, with increasing frequency of hospitalization, the use of invasive procedures, increased exposure to broad-spectrum antibiotics, the widespread antibiotic prophylaxis with fluoroquinolones and change in the profile of pathogens causing spontaneous bacterial peritonitis. Now, multi-drug resistant pathogens resistant to antibiotics from 3 or more groups, including β-lactams – are increasingly isolated. SBP was divided into nosocomial (hospital acquired), health-care associated (HCA) and community acquired (CA). This division commonly reflects antibiotic resistance of the pathogens. Due to variation of SBP producing organism, the first-line empirical antibiotic therapy should be chosen according to the local epidemiology. Characteristics of SBP-inducing pathogens vary depending on where the infection was acquired. In hospital-acquired infections, multi-drug resistant pathogens are more often cultivated, which in turn contributes to less effective treatment and worse prognosis. The diagnosis of SBP is based on diagnostic paracentesis the greatest sensitivity for the diagnosis of SBP is reached with a cut-off neutrophil count of 250/mm³, although the greatest specificity is reached with a cut-off of 500 neutrophils/mm³. Ascites culture is essential to guide antibiotic therapy. Patients with an ascitic fluid neutrophil count ≥250 cells/mm³ and negative culture have culture-negative SBP. Some patients have ‘bacterascites’ in which cultures are positive but there is normal ascitic neutrophil count (<250/mm³). Spontaneous fungal peritonitis is sporadic, less known, but observational records suggest a poorer prognosis. According to EASL clinical guidelines in management of patients with decompensated cirrhosis concerning management of SBP, the option of antibiotic treatment should be depended on the knowledge of origin of the infection, the presence of individual risk for multi drug resistant bacteria and the local microbiology. Third-generation cephalosporins are recommended as first-line antibiotic treatment for community-acquired SBP in countries with low rates of bacterial resistance. In countries with high rates of bacterial resistance piperacillin/tazobactam or carbapenem should be considered. The effectiveness of antibiotic therapy should be checked with a second paracentesis at 48 hours from starting treatment. Failure of first-line antibiotic therapy should be expected if there is worsening of clinical signs and symptoms and/or increase or no obvious reduction in leucocyte count (at least 25%) in 48 h. The duration of treatment should be at least 5-7 days. Patients with SBP have an increased incidence of hepatorenal syndrome, which may be associated with reduction of the effective volume of blood supply to the kidneys as consequence to infection. Consequently, in addition to antibiotic therapy in the treatment of SBP, intravenous infusions of albumin in a dose of 1.5 g/kg on the day of diagnosis and 1 g/kg on the third day should be used. Because most attacks of SBP are believed to result from the translocation of enteric gram-negative bacteria, the ideal prophylactic agent should be safe, affordable and effective at decreasing the amounts of...
these organisms from the gut while preserving the protective anaerobic flora. These prophylactic antibiotics must be firmly restricted to patients at high risk of SBP. Three high-risk patient populations have been identified: i) patients with acute GI hemorrhage; ii) patients with low total protein content in ascitic fluid and no prior history of SBP (primary prophylaxis) and iii) patients with a previous history of SBP (secondary prophylaxis). Primary prophylaxis with norfloxacín (400 mg/day) in patients with Child-Pugh score ≥ 9 and serum bilirubin level ≥ 3 mg/dl, with either impaired renal function or hyponatraemia, and ascitic fluid protein lower than 15 g/L is recommended.

### Infections Other Than SBP
Throughout hospitalization about 25-30% of cirrhotic patients have non-SBP infections frequently, urinary tract, pneumonia, skin and soft tissue infections, and bacteraemia. Nearly, 60% of non-SBP infections were health care associated or nosocomial of origin. In this population, the highest risk for 30-day mortality was related to age, hepatic encephalopathy, serum sodium, and albumin levels. In particular, non-SBP infections, known as frequent precipitating factors for ACLF. The initial presentation of many bacterial infection may be subtle and not very specific, so that, the clinical suspicion is vital. Indeed, all cirrhotic patients should be considered as potentially infected until proven otherwise. To optimize the empirical antibiotic treatment, it is reasonably important to differentiate between community acquired, hospital-acquired, urinary tract infection and a variety of other infections.

### Conclusions
Bacterial infection is universal in cirrhotic patients and accounts for major morbidity and mortality in these groups of patients. Cirrhotic patients are immunocompromised one with high susceptibility to develop spon-taneous bacterial infections, hospital-acquired infections, and ascitic fluid protein lower than 15 g/L is recommended.

### Reference


29. Shindo M, Ken A, Okuno T. Varying incidence of cirrhosis and hepatocel-


38- Assimakopoulos S. Uncovering the molecular events associated with increased intestinal permeability in liver cirrhosis: the pivotal role of enterocyte tight junctions and future perspectives. *J. Hepatol.* 2013; 59 (5): 1144-1146.


